Eli Health Wins a Global Recognition Award 2026
A health-conscious professional in Toronto wakes up, picks up a thermometer-shaped cartridge from her bathroom counter, places the collection pad in her mouth for 30 seconds, snaps a photo through her smartphone app, and receives her morning cortisol reading within minutes. The chronic question of whether her sleep, stress, and energy patterns are reflected in her actual hormonal data, historically answerable only after a laboratory visit and a multi-day wait, is now resolved before she finishes her coffee. The platform that orchestrated this transformation is Eli Health. This Montréal-headquartered women-led healthtech company has won a 2026 Global Recognition Award for category-defining work in instant hormone monitoring. The Hormometer, the company’s flagship product, earned the Best of Innovation in Digital Health award at the 2025 Consumer Electronics Show and demonstrates upwards of 80% agreement with lab-grade ELISA cortisol measurements, as demonstrated in third-party validation studies, all delivered from saliva to smartphone in minutes.
Technical Innovation and Architecture
Eli Health combines four engineering domains under a single regulated product: a proprietary biochemistry assay capable of detecting hormones at clinically meaningful concentrations from saliva, custom hardware manufactured in-house, a computer vision and machine learning pipeline that uses the smartphone camera to analyze test cartridge color intensity and pattern, and an endocrinology-informed analytics layer that converts raw biomarker readings into trend insights and AI-powered recommendations. The platform incorporates more than 12 patent-pending innovations spanning biochemistry, hardware, software, artificial intelligence, and endocrinology. The launch portfolio covers two biomarkers: a Cortisol Hormometer operating under FDA general wellness guidelines and a Progesterone Hormometer registered with the United States Food and Drug Administration, with Health Canada approval targeted in 2025.
The architectural significance lies in compressing a process that historically required laboratory infrastructure, sample shipment, and multi-day analysis into a single consumer-held cartridge and smartphone application. Where traditional testing captures point-in-time snapshots, the Hormometer enables continuous longitudinal tracking of biomarkers whose rhythms, daily, monthly, and life-stage, are central to clinical interpretation. Cortisol typically peaks in the morning and declines toward bedtime, with the rhythm disrupted by stress, poor sleep, irregular eating, and light exposure, none of which standard lab tests can capture in a snapshot. The R&D pipeline extends to testosterone and estradiol, the form of estrogen that declines during menopause, positioning the platform as a comprehensive hormonal health interface rather than a single-biomarker point solution.
Market Strategy and Leadership
The commercial model is a subscription-based consumer health platform that begins at $8 per test with a 12-month commitment, generating recurring revenue per active user while maintaining affordable pricing relative to laboratory testing alternatives. Vertical integration from biochemistry through hardware to software and endocrinology allows Eli Health to compress unit economics that competing at-home test providers must split with laboratory partners and shipping logistics networks. In-house manufacturing supports quality control, supply chain ownership, and capital efficiency at scale. Beta access launched in the United States and Canada in January 2025, with public launch targeted for later that year, supported by a waitlist for progesterone monitoring that has drawn substantial consumer interest.
Leadership combines founder execution with institutional alignment on women’s health investing. Co-founder and CEO Marina Pavlovic Rivas has framed the company’s mission as building a real-time interface to the human body, explicitly analogizing the Hormometer to a glucometer for hormonal health. Co-founder and CTO Thomas Cortina leads the technical organization. The June 2025 Series A round of $12 million USD ($17 million CAD) was led by BDC Capital’s Thrive Venture Fund, qualifying as one of the largest single financings for a Canadian women’s health technology startup. The investor syndicate includes Muse Capital, Telus Global Ventures, Accelia Capital, Rocana Ventures, Foreground Capital, Real Ventures, Leva Capital, and Garage Capital, with cumulative funding now reaching approximately $20 million USD. “We are creating unprecedented access to hormone health insights, providing individuals with the tools they need to understand better and support their wellness, every day and across life,” Pavlovic Rivas has stated.
Industry Impact and Future Vision
The market opportunity is substantial. Approximately 60% of adults experience symptoms related to hormonal imbalances, and cortisol dysregulation alone affects roughly one in three adults, yet continuous monitoring has remained largely inaccessible through traditional laboratory testing. The Hormometer addresses this structural gap by delivering instant readings to a smartphone app, supporting longitudinal tracking, AI-powered recommendations, and trend visualization in a single integrated experience. The product also addresses a meaningful equity dimension: women’s health technology has been historically underfunded, and biomarkers central to fertility, menstrual health, menopause, and pregnancy have lacked an accessible, continuous monitoring infrastructure. Eli Health’s $8-per-test subscription pricing and BDC Thrive-led capital base materially expand both consumer affordability and institutional commitment to women’s health innovation.
The forward roadmap extends the biomarker library from cortisol and progesterone to testosterone and estradiol, with the broader vision of building a continuous, real-time interface to the human body across the most clinically and behaviorally relevant hormones. Just as the thermometer and glucometer transformed health management for hundreds of millions of people, Eli Health is positioning hormonal monitoring for the next category-defining wave of consumer health infrastructure. The combination of regulatory rigor, manufacturing control, AI-driven analytics, CES Best of Innovation recognition, and institutional venture validation justifies the 2026 Global Recognition Award. Eli Health has built what consumer hormonal health has long required: an instant, regulated, AI-powered, consumer-priced platform that turns invisible biological signals into everyday health decisions.
- World’s first instant saliva-based hormone monitoring system, delivering results in minutes rather than the days required by traditional lab testing.
- 12+ patent-pending innovations spanning biochemistry, hardware, software, artificial intelligence, and endocrinology.
- Proprietary smartphone-based computer vision and machine learning pipeline analyzes test cartridge color intensity and pattern for instant biomarker readings.
- FDA-registered Progesterone Hormometer and FDA general wellness positioning for Cortisol Hormometer, with Health Canada approval targeted in 2025.
- In-house manufacturing capability supports quality control, supply chain ownership, and capital-efficient scaling.
- 80%+ agreement with lab-grade ELISA cortisol measurement based on third-party validation studies, providing clinical-adjacent accuracy in a consumer device.
- Six years of focused R&D from 2019 founding to commercial readiness for two biomarkers (cortisol and progesterone).
- Hormometer earned CES 2025 Best of Innovation in Digital Health award, recognizing the device as a category-defining breakthrough in personalized consumer health.
- Third-party validation studies completed prior to commercial launch, confirming accuracy and reproducibility of results.
- Private beta program launched in the United States and Canada in January 2025, with early adopters integrating the Hormometer into daily health routines.
- Subscription pricing begins at $8 per test with a 12-month commitment, supporting affordable continuous monitoring at scale.
- Public launch targeted for late 2025 with progesterone waitlist already drawing substantial consumer interest.
- $20 million USD ($28 million CAD) raised cumulatively across three rounds since 2019, including a $12 million USD Series A in June 2025.
- Series A led by BDC Capital’s Thrive Venture Fund, qualifying as one of the largest single financings for a Canadian women’s health technology startup.
- Investor syndicate includes BDC Thrive, Muse Capital, Telus Global Ventures, Accelia Capital, Rocana Ventures, Foreground Capital, Real Ventures, Leva Capital, and Garage Capital.
- Female-founded and female-led, with female-investor anchors aligning institutional capital with women’s health domain expertise.
- Strategic positioning as the glucometer-equivalent for hormonal health, framing the Hormometer as a category-defining breakthrough in consumer biomarker monitoring.
- Biomarker roadmap extends from cortisol and progesterone at launch to testosterone and estradiol in development, expanding the addressable market and lifetime value per user.
- Instant results delivered from saliva to smartphone app in minutes, eliminating laboratory shipment, processing delays, and multi-day waiting periods.
- Thermometer-shaped single-use testing cartridge with collection pad designed for ease of use, requiring no specialized training.
- AI-powered recommendations and trend reporting integrated into the smartphone application, supporting longitudinal interpretation of biomarker patterns.
- Subscription-based pricing of $8 per test with 12-month commitment provides predictable consumer cost structure with flexible options available.
- Beta available in the United States and Canada, with iOS and Android smartphone application support.
- Color-coded cartridges for different hormones support visual differentiation and reduce user error in multi-biomarker households
- Direct alignment with women’s health and underserved consumer health categories, addressing biomarkers central to fertility, menstrual health, menopause, and pregnancy.
- Affordable subscription pricing of $8 per test materially expands access for consumers historically priced out of laboratory hormonal testing.
- Backing from BDC Capital’s Thrive Venture Fund, the women-focused fund within Canada’s national development bank, represents institutional commitment to women’s health innovation.
- In-house manufacturing supports direct quality control and reduces dependence on third-party fabricators for critical health diagnostic infrastructure.
- AI recommendation layer is designed to support self-management of stress, energy, and hormonal patterns rather than replace clinical care, framing the product as complementary to medical guidance.
- Female-led leadership team and majority-female board provide representation in a category that has been structurally underrepresented in healthtech entrepreneurship and venture funding.
